Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Valdic 100 Retard tablets
1001010C0CHAAAF
|
Valdic | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Valdic 75 Retard tablets
1001010C0CHABAL
|
Valdic | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Volraman 25mg gastro-resistant tablets
1001010C0BFAAAD
|
Volraman | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Volraman 50mg gastro-resistant tablets
1001010C0BFABAE
|
Volraman | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Volsaid Retard 100 tablets
1001010C0BSABAF
|
Volsaid | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Volsaid Retard 75 tablets
1001010C0BSAAAL
|
Volsaid | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Voltarol 25mg gastro-resistant tablets
1001010C0BBAAAD
|
Voltarol (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Voltarol 50mg dispersible tablets
1001010C0BBAGAJ
|
Voltarol (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Voltarol 50mg gastro-resistant tablets
1001010C0BBABAE
|
Voltarol (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Voltarol 75mg SR tablets
1001010C0BBAHAL
|
Voltarol (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Voltarol Active 4% spray
1003020U0BIAAAH
|
Voltarol Active | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.